Distinguished in Epilepsy with Myoclonic-Atonic Seizures

Archana Desurkar

Sheffield, ENG, GB 
Distinguished in Epilepsy with Myoclonic-Atonic Seizures
Sheffield, ENG, GB 
OverviewLocationsClinical Research

Overview

Archana Desurkar practices in Sheffield, United Kingdom. Ms. Desurkar is rated as a Distinguished expert by MediFind in the treatment of Epilepsy with Myoclonic-Atonic Seizures. Her top areas of expertise are Myoclonic Epilepsy, Epilepsy with Myoclonic-Atonic Seizures, Dravet Syndrome, and Epilepsy.

Her clinical research consists of co-authoring 14 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Epilepsy with Myoclonic-Atonic Seizures.

Gender
Female

Locations

Sheffield, ENG S102TH, United Kingdom
Other Locations
Evelina Children's and St Thomas' Hospitals
London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Multi-centre Randomised, Double Blind, Placebo Controlled Trial to Assess the Role of Intravenous Immunoglobulin in the Management of Children With Encephalitis
A Phase III Multi-centre Randomised, Double Blind, Placebo Controlled Trial to Assess the Role of Intravenous Immunoglobulin in the Management of Children With Encephalitis
Enrollment Status: Completed
Publish Date: March 04, 2024
Intervention Type: Drug
Study Drug: Immunoglobulins
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
Enrollment Status: Terminated
Publish Date: June 16, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

14 Total Publications

The use of cannabidiol in patients with Lennox-Gastaut syndrome and Dravet syndrome in the UK Early Access Program: A retrospective chart review study.
The use of cannabidiol in patients with Lennox-Gastaut syndrome and Dravet syndrome in the UK Early Access Program: A retrospective chart review study.
Journal: Epilepsy & behavior reports
Published: June 14, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Desurkar's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile